Leerink Partnrs Has Strong Estimate for ELDN FY2025 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Analysts at Leerink Partnrs upped their FY2025 EPS estimates for Eledon Pharmaceuticals in a research note issued on Sunday, November 23rd. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings per share of ($0.64) for the year, up from their prior forecast of ($0.86). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Leerink Partnrs also issued estimates for Eledon Pharmaceuticals’ Q4 2025 earnings at ($0.21) EPS, FY2026 earnings at ($0.78) EPS, FY2027 earnings at ($0.82) EPS, FY2028 earnings at ($0.79) EPS and FY2029 earnings at ($0.87) EPS.

A number of other brokerages have also issued reports on ELDN. Zacks Research lowered shares of Eledon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 18th. Guggenheim dropped their target price on shares of Eledon Pharmaceuticals from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eledon Pharmaceuticals in a research report on Monday. Finally, HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Eledon Pharmaceuticals in a research report on Tuesday, September 2nd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.67.

Eledon Pharmaceuticals Trading Down 7.2%

ELDN opened at $1.55 on Wednesday. The stock has a market cap of $92.89 million, a price-to-earnings ratio of -1.46 and a beta of 0.63. The stock has a fifty day moving average price of $2.77 and a 200 day moving average price of $2.89. Eledon Pharmaceuticals has a 1 year low of $1.35 and a 1 year high of $5.08.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.01.

Institutional Trading of Eledon Pharmaceuticals

Several large investors have recently bought and sold shares of ELDN. Zimmer Partners LP increased its position in Eledon Pharmaceuticals by 86.1% in the 3rd quarter. Zimmer Partners LP now owns 1,825,000 shares of the company’s stock valued at $4,727,000 after acquiring an additional 844,318 shares during the period. Velan Capital Investment Management LP increased its stake in shares of Eledon Pharmaceuticals by 2.4% in the 3rd quarter. Velan Capital Investment Management LP now owns 346,973 shares of the company’s stock valued at $899,000 after acquiring an additional 8,000 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Eledon Pharmaceuticals by 78.3% during the 3rd quarter. Bank of America Corp DE now owns 45,229 shares of the company’s stock worth $117,000 after purchasing an additional 19,862 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in Eledon Pharmaceuticals by 116.8% in the third quarter. Squarepoint Ops LLC now owns 36,297 shares of the company’s stock worth $94,000 after acquiring an additional 19,553 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in Eledon Pharmaceuticals by 143.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,154 shares of the company’s stock valued at $31,000 after purchasing an additional 7,166 shares during the period. 56.77% of the stock is owned by institutional investors and hedge funds.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).